Phase I/Developmental Therapeutics Program

The Phase I/Developmental Therapeutics Program is a multidisciplinary scientific focus group designed to develop new methods for the treatment of malignancy. The program includes a team of medical oncologists, nurses, research scientists, data coordinators and social workers who have extensive experience in providing novel therapeutic strategies.

Through this program, patients and referring physicians have access to the newest and most promising anti-cancer treatments supported by both the National Cancer Institute and pharmaceutical companies. Patients with a variety of malignancies are typically eligible to receive these treatments. The Team meets weekly to discuss current and pending protocols and to review all patients on study trials.

Staff of this Program:
Robert DiPaola, MD, Director and Medical Oncologist
Joseph Aisner, MD, Medical Oncologist
Mecide Gharibo, MD, Medical Oncologist
Ned Lattime, PhD, Researcher
Janice Mehnert, MD, Medical Oncologist
Rebecca Moss, MD, Medical Oncologist
Elizabeth Poplin, MD, Medical Oncologist
Mark Stein, MD, Medical Oncologist
Antoinette Tan, MD, Medical Oncologist
Beth Knox, RN, APN, Advanced Practice Nurse
Joan Quagliata, RN, Primary Treatment Nurse
Aggie Wong, RN, Primary Treatment Nurse
Stephanie Beers, RN, Research Nurse
Phaedra Kirin, RN, Research Nurse
Cecilila Thomas, RN, Research Nurse
Jane Fisher, RN, Research Nurse
Barbara Hale, MSW, Social Worker
Anna Wong, CRC, Clinical Research Review Specialist
Shari Adams, Clinical Research Review Specialist
Simantini Eddy, Clinical Research Review Specialist
Anupama Mitta, Clinical Research Review Specialist
Elayne Wesolowsky, Clinical Research Review Specialist
Kelly Taber Levinson, Clinical Research Review Specialist

The Cancer Institute of New Jersey

Robert Wood Johnson Medical School

University of Medicine and Dentistry of New Jersey